Chimerix
deal term summary emergent is an experienced company collaborating with government agencies to protect public health terms summary million received at closing in up to an additional million in potential procurement milestones royalty on future gross profit with volumes above million courses of therapy royalty of all international gross profit up to an additional million in development milestones a oral suspension tablets tembe me | Chimerix
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
41 of 43
Similar slides by Chimerix
See diffirences between slides (animation)
Investor Presentation
May 2023
deal term summary emergent is an experienced company collaborating with government agencies to protect public health terms summary oral suspension tablets | Chimerix
Investor Presentation
March 2023
deal term summary company collaborating with government agencies to protect public health terms oral suspension tablets procurement milestones royalty on future gross profit with volumes above million courses of therapy be | Chimerix
Related slides by other companies
Billtrust
Results
August 2021
adjusted gross profit and adjusted gross margin | Billtrust
Billtrust
Results
November 2021
adjusted gross profit margin margin | Billtrust
Gett
SPAC
November 2021
of direct gross profit upside potential from just existing clients | Gett
Billtrust
Results
August 2022
adjusted gross profit margin | Billtrust
Other recent decks by Chimerix
See all presentations (6 decks)
Investor Presentation
May 2023
Investor Presentation
March 2023
Results
March 2022
Investor Conference
November 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights